CureDM

Contact:
Loraine V. Upham
Lori@CureDM.com
(505-515-1947

CureDM Receives IND Approval for Phase 1a Safety Study

Wilmington, DE – July 24, 2012 – CureDM, LLC is pleased to report that the U.S. Food and Drug Administration has approved the company's Investigational New Drug (IND) application to begin human clinical study of Human ProIslet Peptide (HIP2B - formerly referred to as Pancreate) for treatment of diabetes.

Diabetes is manifest when islet mass becomes insufficient to service dietary demands. In Type 2 diabetes, insufficient islet mass is a function of too much demand resulting from increased dietary intake, lack of exercise, subsequent insulin resistance among other factors. In Type 1 diabetes, insufficient islet mass is a function of autoimmune destruction of existing islets. In both type 1 and type 2 diabetes, islets mass is insufficient. HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both indications will be pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX